| Ipilimumab studied in …STUDIED_INderived200 of 681show all (up to 200) |
|---|
| → studied in | NCT01896999Phase 1/Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 681 trials list this drug (203 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · 681 trials list this drug (203 active) | — | — | Malignant Genitourinary System Neoplasm,Large Cell Neuroendocrine Carcinoma,Sarcomatoid Renal Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04751370Phase 2 · active not recruiting Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer · 681 trials list this drug (203 active) | — | — | Malignant Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · 681 trials list this drug (203 active) | — | — | Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma,Endometrial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227012Phase 1/Phase 2 · recruiting Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. · 681 trials list this drug (203 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07401875Phase 1 · recruiting A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · 681 trials list this drug (203 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188118early Phase 1 · completed Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · 681 trials list this drug (203 active) | — | — | Melanoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838974Phase 1 · not yet recruiting Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816345Phase 1 · recruiting Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO · 681 trials list this drug (203 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 681 trials list this drug (203 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715229Phase 2 · terminated Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07291076Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07293351Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314169Phase 2 · active not recruiting Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer · 681 trials list this drug (203 active) | — | — | Anal Canal Squamous Cell Carcinoma,Anal Canal Carcinoma,Malignant Anal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079712Phase 2 · active not recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors · 681 trials list this drug (203 active) | — | — | Neuroendocrine Neoplasm,Neuroendocrine Carcinoma,Large Cell Neuroendocrine Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464759Phase 1/Phase 2 · active not recruiting A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05904080Phase 2 · suspended Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer · 681 trials list this drug (203 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · 681 trials list this drug (203 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03776487Phase 2 · active not recruiting Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer · 681 trials list this drug (203 active) | — | — | Gastric Carcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05048212Phase 2 · recruiting A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases · 681 trials list this drug (203 active) | — | — | Brain Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227415Phase 1/Phase 2 · recruiting Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer · 681 trials list this drug (203 active) | — | — | Carcinoma,Kidney Neoplasm,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04938232Phase 2 · active not recruiting Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL · 681 trials list this drug (203 active) | — | — | Hodgkin Lymphoma,Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532902Phase 1 · recruiting A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer · 681 trials list this drug (203 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453620Phase 1 · active not recruiting Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm,Breast Adenocarcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04462406Phase 2 · active not recruiting Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial · 681 trials list this drug (203 active) | — | — | Melanoma,Melanoma of Unknown Primary,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · 681 trials list this drug (203 active) | — | — | Melanoma,Cutaneous Melanoma,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01134614Phase 2 · active not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery · 681 trials list this drug (203 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530463Phase 2 · active not recruiting Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome · 681 trials list this drug (203 active) | — | — | Leukemia,Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02703623Phase 2 · active not recruiting Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer · 681 trials list this drug (203 active) | — | — | Prostate Adenocarcinoma,Prostate Carcinoma,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03307616Phase 2 · active not recruiting Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery · 681 trials list this drug (203 active) | — | — | Dedifferentiated Liposarcoma,Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04013542Phase 1 · active not recruiting Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer · 681 trials list this drug (203 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06708949Phase 2 · active not recruiting A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02259621Phase 2 · active not recruiting Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · 681 trials list this drug (203 active) | — | — | Malignant Genitourinary System Neoplasm,Malignant Solid Neoplasm,Penile Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02890329Phase 1 · active not recruiting Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia · 681 trials list this drug (203 active) | — | — | Myelodysplastic Syndrome,Secondary Acute Myeloid Leukemia,Secondary Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04080804Phase 2 · active not recruiting Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer · 681 trials list this drug (203 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01274338Phase 3 · active not recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery · 681 trials list this drug (203 active) | — | — | Melanoma,Cutaneous Melanoma,Melanoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03122522Phase 2 · active not recruiting A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04013854Phase 2 · active not recruiting Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06968988Phase 1 · suspended Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma · 681 trials list this drug (203 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188896Phase 2 · recruiting A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04562129Phase 2 · active not recruiting IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721846Phase 1 · completed Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793166Phase 3 · active not recruiting Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · 681 trials list this drug (203 active) | — | — | Rhabdoid Tumor of the Kidney,Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145115Phase 2 · active not recruiting A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden · 681 trials list this drug (203 active) | — | — | Astrocytoma, IDH-Mutant, Grade 4,Diffuse Glioma,Glioblastoma, IDH-Wildtype+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536141Phase 1 · recruiting A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors · 681 trials list this drug (203 active) | — | — | Solid Neoplasm,Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896839Phase 1/Phase 2 · recruiting Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer · 681 trials list this drug (203 active) | — | — | Melanoma,Basal Cell Carcinoma,Skin Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224781Phase 3 · active not recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339571Phase 2/Phase 3 · active not recruiting A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02506153Phase 3 · active not recruiting Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery · 681 trials list this drug (203 active) | — | — | Cutaneous Melanoma,Non-Cutaneous Melanoma,Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06683755Phase 1/Phase 2 · recruiting Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05779423Phase 2 · recruiting Cryoablation+Ipilimumab+Nivolumab in Melanoma · 681 trials list this drug (203 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04039607Phase 3 · completed A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07430202Phase 1 · not yet recruiting A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07689175Phase 2 · recruiting Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02046733Phase 2 · completed Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease · 681 trials list this drug (203 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03141177Phase 3 · completed A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504796Phase 2 · recruiting ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02879695Phase 1 · active not recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia · 681 trials list this drug (203 active) | — | — | B Acute Lymphoblastic Leukemia,Mixed Phenotype Acute Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03274258Phase 2 · terminated Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma,Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03355976Phase 2 · active not recruiting BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas · 681 trials list this drug (203 active) | — | — | Primary Peritoneal Carcinoma,Clear Cell Adenocarcinoma,Malignant Fallopian Tube Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04008030Phase 3 · active not recruiting A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) · 681 trials list this drug (203 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933903Phase 2 · recruiting BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770100Phase 2 · not yet recruiting Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) · 681 trials list this drug (203 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361720Phase 2 · recruiting Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762703Phase 1/Phase 2 · not yet recruiting Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy · 681 trials list this drug (203 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762716Phase 1/Phase 2 · not yet recruiting Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy · 681 trials list this drug (203 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929041Phase 2/Phase 3 · active not recruiting Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative · 681 trials list this drug (203 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06743126Phase 3 · recruiting SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463408early Phase 1 · completed Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma · 681 trials list this drug (203 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03646617Phase 2 · active not recruiting Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840589Phase 1 · suspended Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm,Ovarian Carcinoma,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166406Phase 3 · recruiting Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03502733Phase 1 · active not recruiting Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma · 681 trials list this drug (203 active) | — | — | Lymphoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05407675Phase 1/Phase 2 · completed A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors · 681 trials list this drug (203 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01688492Phase 1/Phase 2 · active not recruiting Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer · 681 trials list this drug (203 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03203473Phase 2 · active not recruiting Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) · 681 trials list this drug (203 active) | — | — | Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06250335Phase 2 · active not recruiting Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195682Phase 1 · recruiting A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05262556Phase 1 · completed NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas · 681 trials list this drug (203 active) | — | — | Digestive System Neuroendocrine Neoplasm,Mixed Neuroendocrine Non-Neuroendocrine Neoplasm,Digestive System Neuroendocrine Tumor+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756190Phase 2 · not yet recruiting Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study · 681 trials list this drug (203 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07751055Phase 2 · recruiting Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer · 681 trials list this drug (203 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07444619Phase 1 · recruiting A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas · 681 trials list this drug (203 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176483Phase 1 · recruiting Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors · 681 trials list this drug (203 active) | — | — | Solid Neoplasm,Head and Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647265Phase 2 · recruiting Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma · 681 trials list this drug (203 active) | — | — | Pleural Biphasic Mesothelioma,Pleural Sarcomatoid Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04887870Phase 2/Phase 3 · completed Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05199285Phase 2 · terminated A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma,BCLC Stage B Hepatocellular Carcinoma,BCLC Stage C Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01024231Phase 1 · completed Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07611825Phase 2 · recruiting Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03604978Phase 1/Phase 2 · active not recruiting Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma · 681 trials list this drug (203 active) | — | — | Meningioma,Grade 2 Meningioma,Grade 3 Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816332Phase 1 · active not recruiting Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers · 681 trials list this drug (203 active) | — | — | Melanoma,Basal Cell Carcinoma,Skin Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914300Phase 2 · active not recruiting Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer · 681 trials list this drug (203 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Oncocytic Carcinoma,Differentiated Thyroid Gland Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06866262Phase 1/Phase 2 · recruiting Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial · 681 trials list this drug (203 active) | — | — | Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04290546Phase 1 · completed CIML NK Cell in Head & Neck Cancer · 681 trials list this drug (203 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04996823Phase 2 · active not recruiting Axitinib + Ipilimumab in Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06097728Phase 3 · active not recruiting MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma · 681 trials list this drug (203 active) | — | — | Pleural Mesothelial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04117087Phase 1 · active not recruiting Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03333616Phase 2 · active not recruiting Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors · 681 trials list this drug (203 active) | — | — | Malignant Genitourinary System Neoplasm,Adrenal Cortical Carcinoma,Malignant Penile Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04413123Phase 2 · active not recruiting Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC · 681 trials list this drug (203 active) | — | — | Papillary Renal Cell Carcinoma,Renal Cell Carcinoma,Collecting Duct Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546686Phase 2 · active not recruiting Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer · 681 trials list this drug (203 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049576Phase 1 · active not recruiting Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01708941Phase 2 · completed Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery · 681 trials list this drug (203 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816358Phase 1 · active not recruiting Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07230613Phase 2 · recruiting Neo-adjuvant Immunotherapy in Patients With Localized Melanoma · 681 trials list this drug (203 active) | — | — | Cutaneous Melanoma,Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07715565Phase 2 · not yet recruiting Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03425331Phase 2 · terminated Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03690986Phase 1 · active not recruiting VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer · 681 trials list this drug (203 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501054Phase 1/Phase 2 · active not recruiting Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07128680Phase 1 · recruiting Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer · 681 trials list this drug (203 active) | — | — | Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05533697Phase 1/Phase 2 · recruiting Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors · 681 trials list this drug (203 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04697576Phase 1 · recruiting Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02648997Phase 2 · active not recruiting An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma · 681 trials list this drug (203 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04465643Phase 1 · completed Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor · 681 trials list this drug (203 active) | — | — | Nerve Sheath Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07355205Phase 1/Phase 2 · recruiting First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03472586Phase 2 · completed Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver · 681 trials list this drug (203 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020070Phase 2 · completed Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06365619Phase 2 · recruiting Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04416568Phase 2 · active not recruiting Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers · 681 trials list this drug (203 active) | — | — | Chordoma,Atypical Teratoid/Rhabdoid Tumor,Rhabdoid Tumor of the Kidney+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04472767Phase 2 · recruiting Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03682276Phase 1/Phase 2 · completed Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05144854Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) · 681 trials list this drug (203 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05584670Phase 1/Phase 2 · recruiting A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors · 681 trials list this drug (203 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03097939Phase 2 · active not recruiting Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma · 681 trials list this drug (203 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · 681 trials list this drug (203 active) | — | — | Spindle Cell Neoplasm,Chordoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04317105Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06364917Phase 2 · recruiting DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03104439Phase 2 · active not recruiting Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04495257Phase 1 · completed A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) · 681 trials list this drug (203 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383441Phase 3 · recruiting Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04500548Phase 1 · withdrawn Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study · 681 trials list this drug (203 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02785952Phase 3 · active not recruiting Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers · 681 trials list this drug (203 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06377111Phase 1 · active not recruiting A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03918252Phase 2 · active not recruiting Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma · 681 trials list this drug (203 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03949153Phase 1/Phase 2 · completed Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510334Phase 2 · recruiting VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03958383Phase 1/Phase 2 · terminated IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042753Phase 2 · completed Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors · 681 trials list this drug (203 active) | — | — | Pituitary Gland Neoplasm,Pituitary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02210117early Phase 1 · active not recruiting Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery · 681 trials list this drug (203 active) | — | — | Clear Cell Renal Cell Carcinoma,Kidney Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02073123Phase 1/Phase 2 · completed Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02231749Phase 3 · completed Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) · 681 trials list this drug (203 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03449108Phase 2 · active not recruiting LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm,Bone Sarcoma,Osteosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498792early Phase 1 · recruiting Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02696993Phase 1/Phase 2 · active not recruiting Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer · 681 trials list this drug (203 active) | — | — | Brain Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04388852Phase 1 · active not recruiting DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers · 681 trials list this drug (203 active) | — | — | Malignant Solid Neoplasm,Urothelial Carcinoma,Clear Cell Renal Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04141644Phase 1 · active not recruiting Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712927Phase 2 · recruiting Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases · 681 trials list this drug (203 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07394062recruiting Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03600155Phase 1 · completed Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome · 681 trials list this drug (203 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03645928Phase 2 · terminated Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors · 681 trials list this drug (203 active) | — | — | Melanoma,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04003649Phase 1 · active not recruiting IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM · 681 trials list this drug (203 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594991Phase 2 · recruiting A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06946797Phase 2 · active not recruiting A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03769155Phase 1 · active not recruiting VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05012254Phase 2 · active not recruiting Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases · 681 trials list this drug (203 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05144529Phase 2 · terminated A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06941857Phase 2 · recruiting NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03799445Phase 2 · terminated Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Oropharyngeal Basaloid Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma,Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03521830Phase 2 · recruiting Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Basal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03789110Phase 2 · active not recruiting NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer · 681 trials list this drug (203 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014776Phase 2 · completed Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer · 681 trials list this drug (203 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06889493Phase 1 · recruiting SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) · 681 trials list this drug (203 active) | — | — | Neuroendocrine Carcinoma,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05219435Phase 2 · completed Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05341349Phase 1 · terminated Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases · 681 trials list this drug (203 active) | — | — | Melanoma,Ocular Melanoma,Melanoma of Unknown Primary+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04396860Phase 2/Phase 3 · completed Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma · 681 trials list this drug (203 active) | — | — | Gliosarcoma,MGMT-Unmethylated Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01604889Phase 1/Phase 2 · terminated A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05836571Phase 2 · active not recruiting Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma · 681 trials list this drug (203 active) | — | — | Liposarcoma,Soft Tissue Sarcoma,Extraskeletal Myxoid Chondrosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07147101recruiting Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04817254Phase 2 · completed Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma · 681 trials list this drug (203 active) | — | — | Glioblastoma,Malignant Glioma,Gliosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03650894Phase 2 · active not recruiting Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients · 681 trials list this drug (203 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05407441Phase 1/Phase 2 · active not recruiting Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · 681 trials list this drug (203 active) | — | — | Chordoma,Atypical Teratoid/Rhabdoid Tumor,Rhabdoid Tumor of the Kidney+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06362369Phase 1/Phase 2 · recruiting A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · 681 trials list this drug (203 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Skin Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07134842Phase 1 · recruiting A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. · 681 trials list this drug (203 active) | — | — | Glioblastoma,Adult Gliosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02668770Phase 1 · terminated Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies · 681 trials list this drug (203 active) | — | — | Malignant Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05289193Phase 2 · active not recruiting CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158129Phase 2 · completed Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03459222Phase 1/Phase 2 · completed An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread · 681 trials list this drug (203 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04709276Phase 2 · active not recruiting A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer · 681 trials list this drug (203 active) | — | — | Prostate Neuroendocrine Carcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05704933early Phase 1 · completed Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases · 681 trials list this drug (203 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02681302Phase 1/Phase 2 · terminated Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence · 681 trials list this drug (203 active) | — | — | Lymphoma,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03377023Phase 1/Phase 2 · active not recruiting Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer · 681 trials list this drug (203 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06581406Phase 2/Phase 3 · recruiting A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma · 681 trials list this drug (203 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06295159Phase 2 · recruiting Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031233Phase 4 · recruiting Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03070392Phase 2 · completed Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma · 681 trials list this drug (203 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07176650Phase 1 · recruiting Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma · 681 trials list this drug (203 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06388369Phase 1/Phase 2 · terminated Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05401786Phase 2 · active not recruiting Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC · 681 trials list this drug (203 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03071406Phase 2 · active not recruiting Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma · 681 trials list this drug (203 active) | — | — | Malignant Skin Neoplasm,Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03999749Phase 2 · active not recruiting A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665348Phase 2/Phase 3 · completed Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy · 681 trials list this drug (203 active) | — | — | Neoplasm,Malignant Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05926960Phase 2 · terminated A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03036098Phase 3 · active not recruiting Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer · 681 trials list this drug (203 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026140Phase 2 · recruiting Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer · 681 trials list this drug (203 active) | — | — | Colon Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223155Phase 1 · active not recruiting Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer · 681 trials list this drug (203 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04091750Phase 2 · active not recruiting Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma · 681 trials list this drug (203 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04969887Phase 2 · active not recruiting Combination Immunotherapy in Rare Cancers Under InvesTigation · 681 trials list this drug (203 active) | — | — | Female Reproductive System Neoplasm,Neuroendocrine Tumor,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03400332Phase 1/Phase 2 · completed A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers · 681 trials list this drug (203 active) | — | — | Malignant Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |